Netherlands' uniQure Q1 revenue misses estimates

uniQure

05/05/2026 12:16

Overview

Netherlands gene therapy firm's Q1 revenue rose yr/yr but missed analyst expectations

Q1 net loss widened to $53.5 mln from $43.6 mln a year earlier

Company ended Q1 with $586.6 mln in cash, expects runway into H2 2029

Outlook

uniQure expects cash to fund operations into the second half of 2029

Result Drivers

LICENSE REVENUE - Q1 revenue increase was driven by higher license revenue compared to the prior year

SG&A EXPENSES - Higher SG&A costs were mainly due to increased hiring and commercial planning for AMT-130

R&D EXPENSES - Lower R&D expenses resulted from decreased contingent consideration, external program spend, personnel, and facilities costs

Company press release: ID:nGNE2XlmkW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$3.60 mln
$5.22 mln (11 Analysts)
Q1 EPS
-$0.85


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Uniqure NV is $35.00, about 69.2% above its May 4 closing price of $20.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)